Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET
WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus Biopharma Corp, Inc. (NASDAQ:ABUS ) Q1 2022 Earnings Conference Call May 5, 2022 8:45 AM ET Company Participants Lisa Caperelli - VP, IR William Collier - President, CEO & Director Michael Sof
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus Biopharma (ABUS) is trading ~4% higher in the pre-market Monday after H.C
Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.

Arbutus Biopharma (ABUS) Q4 2021 Earnings Call Transcript

10:30pm, Thursday, 03'rd Mar 2022 The Motley Fool
ABUS earnings call for the period ending December 31, 2021.
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
Arbutus Biopharma press release (ABUS): FY GAAP EPS of -$0.83 beats by $0.03.Revenue of $11M (+59.2% Y/Y) beats by $0.35M.Shares -0.3% PM.CEO comment: “We formed strategic and…
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma Q4 2021 Earnings Preview

04:52pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q4 results on Thursday, Mar. 3, before market open.Consensus EPS estimate is -$0.20 and consensus revenue estimate is $2.87M.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE